Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06751238 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06751238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06751238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
September 24, 2025
Completion date
March 11, 2031
Enrollment
20 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile psoriatic arthritis